Stratophase, a specialist in real-time chemical and biochemical measurement and detection, has started the new year in style by securing £2.5m follow-on funding from existing investor East Hill Management.  Commenting on the funding, Dr Richard Williams, CEO of Stratophase said, "These are exciting times for Stratophase.  We are initiating a SpectroSens Early Access Programme in key markets and are actively seeking strategic partner organisations with the intention of leveraging this widely applicable technology into multiple end markets".  The additional investment will enable the company to roll out their SpectroSens real-time monitoring technology in target markets.  The roll out will be supported by recruitment of key staff and a move to larger premises.   

Bringing together proven science from the telecoms, optics and biotech industries, the SpectroSens optical microchip platform technology is being developed for a number of applications in process measurement and bio-detection.  Target applications to date include real-time in-line monitoring of pharmaceutical manufacturing (both small molecule and bio-pharmaceuticals), bio-fuel production, bio-detection for security and military defence and point-of-care diagnostics.  The SpectroSens system is currently being trialled by several major organisations including a top tier multinational pharmaceutical company and the UK military. 

For further information about Stratophase and the SpectroSens system, please visit http://www.stratophase.com/.